Jaap C Reijneveld1, Martin J B Taphoorn2, Corneel Coens3, Jacoline E C Bromberg4, Warren P Mason5, Khê Hoang-Xuan6, Gail Ryan7, Mohamed Ben Hassel8, Roelien H Enting9, Alba A Brandes10, Antje Wick11, Olivier Chinot12, Michele Reni13, Guy Kantor14, Brian Thiessen15, Martin Klein16, Eugenie Verger17, Christian Borchers18, Peter Hau19, Michael Back20, Anja Smits21, Vassilis Golfinopoulos22, Thierry Gorlia23, Andrew Bottomley3, Roger Stupp24, Brigitta G Baumert25. 1. Department of Neurology, Brain Tumor Centre Amsterdam, VU University Medical Centre and Academic Medical Centre, Amsterdam, Netherlands. Electronic address: jc.reijneveld@vumc.nl. 2. Department of Neurology, Medical Centre Haaglanden and Leiden University Medical Centre, The Hague, Netherlands. 3. Department of Quality of Life, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium. 4. Department of Neuro-oncology, Erasmus MC University MC Cancer Centre, Rotterdam, Netherlands. 5. Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada. 6. APHP, Department of Neurology, Pitié-Salpêtrière Hospital, UPMC, Sorbonne Universités, IHU, Paris, France. 7. Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 8. Department of Medical Oncology and Department of Radiotherapy, Centre Eugène Marquis, Rennes, France. 9. Department of Neurology, University of Groningen, University Medical Centre, Groningen, Netherlands. 10. Department of Medical Oncology, AUSL-IRCCS Scienze Neurologiche, Bologna, Italy. 11. Neurology Clinic, University of Heidelberg Medical Centre and NCT Neurooncology in DKTK of the German Cancer Research Center (DKFZ), Heidelberg, Germany. 12. Aix Marseille Universite, APHM, Hopital de La Timone, Department of Neuro-Oncology, Marseille, France. 13. IRCCS San Raffaele Scientific Institute, Milan, Italy. 14. Department of Radiotherapy, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, Bordeaux, France; Department of Radiotherapy, University Bordeaux Segalen, Bordeaux, France. 15. BC Cancer Agency, Vancouver, BC, Canada. 16. Department of Medical Psychology, Brain Tumor Centre Amsterdam, VU University Medical Centre and Academic Medical Centre, Amsterdam, Netherlands. 17. Department of Radiation-Oncology, Hospital Clinic Universitari, Barcelona, Spain. 18. Department of Neurology, University Hospital Tübingen, Tübingen, Germany; Centre of Neuromedicine, North-West-Hospital Sanderbusch, Sande, Germany. 19. Department of Neurology, University Hospital Regensburg, Regensburg, Germany. 20. Department of Radiation Oncology, Royal North Shore Hospital, St Leonards, NSW, Australia. 21. Department of Neuroscience, Neurology, Uppsala University and University Hospital, Uppsala, Sweden. 22. Medical Department, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium. 23. Department of Statistics, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium. 24. Department of Clinical Neurosciences, Department of Neurosurgery, and Department of Oncology, University Hospital Lausanne, Lausanne, Switzerland. 25. Department of Medical Oncology and Cancer Centre, University Hospital Zurich, Zurich, Switzerland; Department of Radiation-Oncology (MAASTRO), Maastricht University Medical Centre (MUMC) and GROW (School for Oncology), Maastricht, Netherlands; Department of Radiation-Oncology, MediClin Robert-Janker-Clinic, Clinical Cooperation Unit Neuro-oncology, University Bonn Medical Centre, Bonn, Germany.
Abstract
BACKGROUND:Temozolomide chemotherapy versus radiotherapy in patients with a high-risk low-grade glioma has been shown to have no significant effect on progression-free survival. If these treatments have a different effect on health-related quality of life (HRQOL), it might affect the choice of therapy. We postulated that temozolomide compromises HRQOL and global cognitive functioning to a lesser extent than does radiotherapy. METHODS: We did a prospective, phase 3, randomised controlled trial at 78 medical centres and large hospitals in 19 countries. We enrolled adult patients (aged ≥18 years) with histologically confirmed diffuse (WHO grade II) astrocytoma, oligodendroglioma, or mixed oligoastrocytoma, with a WHO performance status of 2 or lower, without previous chemotherapy or radiotherapy, who needed active treatment other than surgery. We randomly assigned eligible patients (1:1) using a minimisation technique, stratified by WHO performance status (0-1 vs 2), age (<40 years vs ≥40 years), presence of contrast enhancement on MRI, chromosome 1p status (deleted vs non-deleted vs indeterminate), and the treating medical centre, to receive either radiotherapy (50·4 Gy in 28 fractions of 1·8 Gy for 5 days per week up to 6·5 weeks) or temozolomide chemotherapy (75 mg/m2 daily, for 21 of 28 days [one cycle] for 12 cycles). The primary endpoint was progression-free survival (results published separately); here, we report the results for two key secondary endpoints: HRQOL (assessed using the European Organisation for Research and Treatment of Cancer's [EORTC] QLQ-C30 [version 3] and the EORTC Brain Cancer Module [QLQ-BN20]) and global cognitive functioning (assessed using the Mini-Mental State Examination [MMSE]). We did analyses on the intention-to-treat population. This study is closed and is registered at EudraCT, number 2004-002714-11, and at ClinicalTrials.gov, number NCT00182819. FINDINGS: Between Dec 6, 2005, and Dec 21, 2012, we randomly assigned 477 eligible patients to eitherradiotherapy (n=240) or temozolomide chemotherapy (n=237). The difference in HRQOL between the two treatment groups was not significant during the 36 months' follow-up (mean between group difference [averaged over all timepoints] 0·06, 95% CI -4·64 to 4·75, p=0·98). At baseline, 32 (13%) of 239 patients who received radiotherapy and 32 (14%) of 236 patients who received temozolomide chemotherapy had impaired cognitive function, according to the MMSE scores. After randomisation, five (8%) of 63 patients who received radiotherapy and three (6%) of 54 patients who received temozolomide chemotherapy and who could be followed up for 36 months had impaired cognitive function, according to the MMSE scores. No significant difference was recorded between the groups for the change in MMSE scores during the 36 months of follow-up. INTERPRETATION: The effect of temozolomide chemotherapy or radiotherapy on HRQOL or global cognitive functioning did not differ in patients with low-grade glioma. These results do not support the choice of temozolomide alone over radiotherapy alone in patients with high-risk low-grade glioma. FUNDING: Merck Sharp & Dohme-Merck & Co, National Cancer Institute, Swiss Cancer League, National Institute for Health Research, Cancer Research UK, Canadian Cancer Society Research Institute, National Health and Medical Research Council, European Organisation for Research and Treatment of Cancer Cancer Research Fund.
RCT Entities:
BACKGROUND:Temozolomide chemotherapy versus radiotherapy in patients with a high-risk low-grade glioma has been shown to have no significant effect on progression-free survival. If these treatments have a different effect on health-related quality of life (HRQOL), it might affect the choice of therapy. We postulated that temozolomide compromises HRQOL and global cognitive functioning to a lesser extent than does radiotherapy. METHODS: We did a prospective, phase 3, randomised controlled trial at 78 medical centres and large hospitals in 19 countries. We enrolled adult patients (aged ≥18 years) with histologically confirmed diffuse (WHO grade II) astrocytoma, oligodendroglioma, or mixed oligoastrocytoma, with a WHO performance status of 2 or lower, without previous chemotherapy or radiotherapy, who needed active treatment other than surgery. We randomly assigned eligible patients (1:1) using a minimisation technique, stratified by WHO performance status (0-1 vs 2), age (<40 years vs ≥40 years), presence of contrast enhancement on MRI, chromosome 1p status (deleted vs non-deleted vs indeterminate), and the treating medical centre, to receive either radiotherapy (50·4 Gy in 28 fractions of 1·8 Gy for 5 days per week up to 6·5 weeks) or temozolomide chemotherapy (75 mg/m2 daily, for 21 of 28 days [one cycle] for 12 cycles). The primary endpoint was progression-free survival (results published separately); here, we report the results for two key secondary endpoints: HRQOL (assessed using the European Organisation for Research and Treatment of Cancer's [EORTC] QLQ-C30 [version 3] and the EORTC Brain Cancer Module [QLQ-BN20]) and global cognitive functioning (assessed using the Mini-Mental State Examination [MMSE]). We did analyses on the intention-to-treat population. This study is closed and is registered at EudraCT, number 2004-002714-11, and at ClinicalTrials.gov, number NCT00182819. FINDINGS: Between Dec 6, 2005, and Dec 21, 2012, we randomly assigned 477 eligible patients to either radiotherapy (n=240) or temozolomide chemotherapy (n=237). The difference in HRQOL between the two treatment groups was not significant during the 36 months' follow-up (mean between group difference [averaged over all timepoints] 0·06, 95% CI -4·64 to 4·75, p=0·98). At baseline, 32 (13%) of 239 patients who received radiotherapy and 32 (14%) of 236 patients who received temozolomide chemotherapy had impaired cognitive function, according to the MMSE scores. After randomisation, five (8%) of 63 patients who received radiotherapy and three (6%) of 54 patients who received temozolomide chemotherapy and who could be followed up for 36 months had impaired cognitive function, according to the MMSE scores. No significant difference was recorded between the groups for the change in MMSE scores during the 36 months of follow-up. INTERPRETATION: The effect of temozolomide chemotherapy or radiotherapy on HRQOL or global cognitive functioning did not differ in patients with low-grade glioma. These results do not support the choice of temozolomide alone over radiotherapy alone in patients with high-risk low-grade glioma. FUNDING: Merck Sharp & Dohme-Merck & Co, National Cancer Institute, Swiss Cancer League, National Institute for Health Research, Cancer Research UK, Canadian Cancer Society Research Institute, National Health and Medical Research Council, European Organisation for Research and Treatment of Cancer Cancer Research Fund.
Authors: Taeryool Koo; Do Hoon Lim; Ho Jun Seol; Yun-Sik Dho; Il Han Kim; Jong Hee Chang; Jeongshim Lee; Tae-Young Jung; Ho-Shin Gwak; Kwan Ho Cho; Chang-Ki Hong; Ik Jae Lee; El Kim; Jin Hee Kim; Yong-Kil Hong; Hong Seok Jang; Chae-Yong Kim; In Ah Kim; Sung Hwan Kim; Young Il Kim; Eun-Young Kim; Woo Chul Kim; Semie Hong Journal: J Neurooncol Date: 2018-08-10 Impact factor: 4.130
Authors: David Schiff; Martin Van den Bent; Michael A Vogelbaum; Wolfgang Wick; C Ryan Miller; Martin Taphoorn; Whitney Pope; Paul D Brown; Michael Platten; Rakesh Jalali; Terri Armstrong; Patrick Y Wen Journal: Neuro Oncol Date: 2019-07-11 Impact factor: 12.300
Authors: P D Delgado-López; E M Corrales-García; J Martino; E Lastra-Aras; M T Dueñas-Polo Journal: Clin Transl Oncol Date: 2017-03-02 Impact factor: 3.405
Authors: Philipp Karschnia; Frank J Barbiero; Michaela H Schwaiblmair; Leon D Kaulen; Joseph M Piepmeier; Anita J Huttner; Kevin P Becker; Robert K Fulbright; Joachim M Baehring Journal: Neurooncol Pract Date: 2019-07-06